Pyrazinoylguanidine

Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride. Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation[1].

60398-24-5

PZG

12352005

H302-H315-H319-H335

Drug Derivative

Others

Cardiovascular Disease; Metabolic Disease

N=C(N)NC(C1=CN=CC=N1)=O

C6H7N5O

165.15

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

[1]Vesell ES, et al. Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus. Toxicology. 2000 Apr 3;144 (1-3) :5-11.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W343043/

Reference compound2

No Development Reported